Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,311 JPY
Change Today +17.00 / 1.31%
Volume 822.3K
8086 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 2:00 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

nipro corp (8086) Snapshot

Open
¥1,299
Previous Close
¥1,294
Day High
¥1,316
Day Low
¥1,293
52 Week High
07/27/15 - ¥1,325
52 Week Low
10/17/14 - ¥853.00
Market Cap
224.8B
Average Volume 10 Days
870.3K
EPS TTM
¥82.32
Shares Outstanding
171.5M
EX-Date
09/28/15
P/E TM
15.9x
Dividend
¥34.50
Dividend Yield
2.48%
Current Stock Chart for NIPRO CORP (8086)

Related News

No related news articles were found.

nipro corp (8086) Related Businessweek News

View More BusinessWeek News

nipro corp (8086) Details

Nipro Corporation, together with its subsidiaries, engages in the medical equipment, pharmaceuticals, and glass businesses in Japan, the United States, Europe, and rest of Asia. The company’s Medical-Related Business segment offers injection and infusion products, artificial organ products, functional products, dialysis products, and diabetic products, as well as renal, intervention and anesthesiology, cardiopulmonary, and pharmaceutical kit products. Its Pharmaceutical-Related Business segment provides injectable drugs, including injection kits, etc.; oral drugs, such as orally-disintegrating tablets, etc.; generic anti-cancer drugs and biosimilars; and drugs for external use. The company’s Glass-Related Business segment offers tube glass for pharmaceuticals, vials, and ampoules; and glass material products for thermos bottles and lighting. Nipro Corporation is also involved in the rental of real estate properties. The company was founded in 1954 and is headquartered in Osaka, Japan.

23,153 Employees
Last Reported Date: 06/26/15
Founded in 1954

nipro corp (8086) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nipro corp (8086) Key Developments

Nipro and Otsuka Sign Agreement to Provide TB Drug Delamanid in Indonesia

Nipro and Otsuka Pharmaceutical have entered into a collaboration with Japan International Cooperation Agency to support the Indonesian government's efforts to control its tuberculosis (TB) epidemic, according to Nikkei. Otsuka will provide TB drug delamanid, while Nipro aims to provide for free its app that informs patients when to take the treatment. Nipro also plans to sell TB detection kits as early as spring 2016.

Nipro Corporation Announces Consolidated and Unconsolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the Six Months Ending September 30 2015 and for the Year Ending March 31, 2016

Nipro Corporation announced consolidated and unconsolidated earnings results for the year ended March 31, 2015. For the year, on consolidated basis, the company reported net sales of JPY 325,084 million compared to JPY 300,752 million a year ago. Operating income was JPY 16,571 million compared to JPY 12,289 million a year ago. Ordinary income was JPY 19,661 million compared to JPY 11,918 million a year ago. Net income was JPY 12,470 million or JPY 80.96 per share compared to JPY 2,861 million or JPY 18.19 per share a year ago. Cash flows from operating activities was JPY 27,981 million compared to JPY 21,552 million a year ago. Income before income taxes and minority interests was JPY 19,908 million compared to JPY 12,891 million a year ago. Payments for purchase of noncurrent assets were JPY 40,680 million compared to JPY 29,239 million a year ago. Payments for retirement of noncurrent assets were JPY 42 million compared to JPY 104 million a year ago. For the year, on unconsolidated basis, the company reported net sales of JPY 208,751 million compared to JPY 188,504 million a year ago. Operating income was JPY 15,345 million compared to JPY 14,774 million a year ago. Ordinary income was JPY 22,335 million compared to JPY 18,084 million a year ago. Net income was JPY 12,018 million or JPY 78.02 per share compared to JPY 11,345 million or JPY 72.13 per share a year ago. Income before income taxes was JPY 19,647 million compared to JPY 18,347 million a year ago. For the six months ending September 30, 2015, the company expects net sales of JPY 174,000 million, operating income of JPY 12,700 million, ordinary income of JPY 9,700 million and net income of JPY 3,950 million or JPY 23.30 per share. For the year ending March 31, 2016, the company expects net sales of JPY 362,000 million, operating income of JPY 27,500 million, ordinary income of JPY 22,500 million and net income of JPY 13,700 million or JPY 80.80 per share.

Nipro Corporation, Annual General Meeting, Jun 26, 2015

Nipro Corporation, Annual General Meeting, Jun 26, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8086:JP ¥1,311.00 JPY +17.00

8086 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 4,076 INR +163.00
Fuso Pharmaceutical Industries Ltd ¥298.00 JPY -1.00
JMS Co Ltd ¥306.00 JPY +4.00
Nikkiso Co Ltd ¥1,201 JPY +26.00
NxStage Medical Inc $14.28 USD +0.29
View Industry Companies
 

Industry Analysis

8086

Industry Average

Valuation 8086 Industry Range
Price/Earnings 15.7x
Price/Sales 0.6x
Price/Book 1.2x
Price/Cash Flow 17.5x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NIPRO CORP, please visit www.nipro.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.